grapesharvester schreef op 12 april 2016 20:14:
NEW YORK (TheStreet) -- Vertex Pharmaceuticals' (VRTX - Get Report) price target was reduced to $112 from $143 at Credit Suisse. The firm maintained its "outperform" rating on the stock.
"We have lowered our numbers a bit in 2016, but more notably we have made significant changes to our long-term Orkambi estimates. These changes specifically relate to lowering our ROW Orkambi price and factoring greater discontinuation impact into our patient model," Credit Suisse wrote in a note.
Wat weet Credit Suisse wat wij nog niet weten (over cystic fibrosis, toekomstig gevaar van discontinuatie gebruik Orkambi)?